Search this site

Dr. Hossam Abdel Maksoud Chief Executive Officer Mohamed AlNadi Vice President, International Expansion and Partnerships (MENA and Africa) Stephen Lawandy Global Head of Strategy & Investor Relations Thomas Ingallinera Vice President of Operations Mathew Cherian Chief Operating Officer Dr. Helmy Nada Fund Manager, Dawah Holdings

We’re here to support your health and your business Contact Information Our Locations : Dawah Holdi Company 26 Galal El-Din El-Desouky Street – 1st Floor – Apartment 3 – Almaza – Cairo Dawah Gypto Company Plot 27 – Industrial Zone – Khanka – Abu Zaabal – Qalyubia Governorate2nd Floor – Inside the premises of Gypto Company New York 131 Sunnyside Blvd ,Plainview, NY 11803 , NEW YORK , USA Get in Touch with Our Team : 01200060637 Email: info@dawahpharma.com +1 347 669 1693 Social Media: Submit

Dr. Hossam Abdel Maksoud Chief Executive Officer Dr. Hossam Abdel Maksoud is the Chief Executive Officer and Founder of Maksoud Pharm Group, with over 30 years of experience in the pharmaceutical and healthcare sector. He began his career in 1993 by establishing Maksoud Pharm Inc., a network of independent retail pharmacies serving communities across the tri-state area. Building on this foundation, he launched Community Care Rx, Inc. in 2010, a long-term care pharmacy dedicated to supporting long-term care facilities across the five boroughs, Long Island, and Westchester. The company expanded further with the opening of its New Jersey location in Totowa in 2013. Following the success of Community Care Rx, Dr. Maksoud founded Community Care Consulting, providing specialized clinical expertise and consulting services to a broad range of healthcare settings. He also established Community Care Specialty Pharmacy, which supports patients with chronic and rare conditions by providing access to advanced therapies, patient guidance, and financial assistance programs. Dr. Maksoud continues to lead the organization’s strategic vision and expansion, focusing on innovative healthcare solutions that improve patient outcomes and enhance community well-being.

Strategic Partnership Signed Between Dawah Pharma LLC (USA) and Bateel Group Holding A strategic partnership agreement has been signed in Cairo between Dawah Pharma LLC (USA) and Bateel Group Holding, in the presence of key industry and government representatives. The agreement aims to upgrade pharmaceutical production lines in compliance with FDA standards and introduce new investments to support the export of Egyptian pharmaceuticals to global markets. This milestone builds on Dawah Pharma’s successful collaborations in Egypt with Gypto Pharma City and Dawah Holdi, reinforcing its commitment to enhancing the competitiveness of the Egyptian pharmaceutical industry, transferring global technologies, and strengthening Egypt’s position as a leading regional hub for pharmaceutical manufacturing and export

Strategic Partnerships Driving Global Pharmaceutical Impact At Dawah Pharmaceuticals, partnerships are more than just collaborations — they are long-term alliances built on shared values, innovation, and a deep commitment to advancing human health. JOIN US Dawah-Holdi International Dawah-Holdi International is a strategic joint venture between Dawah Pharmaceuticals and HoldiPharma, combining extensive pharmaceutical expertise and innovative manufacturing capabilities. This partnership leverages HoldiPharma's robust manufacturing infrastructure in Egypt with Dawah Pharmaceuticals' regulatory knowledge and market access to the United States, creating a synergistic approach to deliver high-quality, FDA-compliant generic medications. Dawah-Gypto International Dawah-Gypto International is a dedicated joint venture between Dawah Pharmaceuticals and Gypto Pharma, one of Egypt’s premier pharmaceutical manufacturing companies. The partnership focuses on modernizing production lines to meet stringent FDA standards, thereby facilitating the export of quality pharmaceutical products from Egypt to the U.S. This strategic collaboration uniquely positions Dawah-Gypto International to deliver cost-effective generic medications that adhere strictly to U.S. regulatory guidelines. QG International QG International is a strategic joint venture between Dawah Pharmaceuticals and QG Medical Devices, one of the Middle ,East's leading manufacturers of advanced medical devices .headquartered in Doha, Qatar This partnership aims to integrate Dawah's pharmaceutical expertise with QG's state-of-the-art production capabilities deliver high-quality, FDA-compliant medical devices and healthcare pipeline solutions. By combining Dawah's strong regulatory foundation and global network with QG's technological innovation and precision engineering, the collaboration paves the way for enhanced accessibility and affordability of world-class medical solutions across regiona .and international markets

GYPTO Pharma Signs Preliminary Agreement with Mozambique Government to Establish Regional Pharmaceutical Distribution Hub Dawah Gypto has signed a preliminary agreement with the Government of Mozambique to establish a regional pharmaceutical distribution hub and a packaging facility for liquid and semi-liquid medications This strategic step reinforces the company’s presence in the Southern African region, enhancing access to high-quality and affordable medicines within SADC countries. The collaboration reflects strong confidence in Dawah Gypto’s capabilities and its commitment to supporting sustainable healthcare development. The project will contribute to improving medicine availability, creating local job opportunities, and advancing technology transfer in the pharmaceutical sector. Dawah Gypto continues to expand its footprint across Africa with a clear vision to elevate healthcare standards and deliver life-saving treatments to communities across the continent.

نيكولاس فارطانيان تطوير الشركات، المؤسس يتمتع نيكولاس فارطانيان بخلفية متنوعة. عمل نيكولاس تحت إشراف عمدة لوس أنجلوس السابق، أنطونيو فيلارايغوسا، كمحلل للتجارة الدولية. خلال فترة عمله في مكتب العمدة، تعاون مع أوستن بيوتْنر لجذب الاستثمارات الأجنبية المباشرة، متعاملًا مع مستثمرين مثل الشيخ محمد بن راشد آل مكتوم من دبي، ورئيس وزراء إنجلترا السابق توني بلير، ونائب الرئيس الأول لشركة Forever 21 كريستوفر لي، وساعد في تأمين مصنع لتصنيع سيارات BYD الكهربائية في لوس أنجلوس. بعد مغادرته المجال العام، انضم نيكولاس إلى مركز لوسكين للابتكار، وهو مركز أبحاث اقتصادي، حيث شارك في صياغة سياسة نظام Feed-in-Tariff (FiT) للضرائب على الطاقة الشمسية على الأسطح التجارية. وقد تم اعتماد هذا النظام بالإجماع من قبل مدينة لوس أنجلوس وإدارة المياه والكهرباء. خلال السنوات الـ13 الماضية، عمل نيكولاس في قطاع الرعاية الصحية، مستكشفًا طرقًا فعّالة لإحداث تغييرات داخل الصناعة، وشغل مناصب تنفيذية في مجالي الأدوية والمختبرات السريرية.

Contact Us for an EB5 or E2 Visa Investment Opportunity Submit

Mathew Cherian Chief Operating Officer Mathew Cherian is the Chief Operating Officer and Co-Founder of the company, bringing more than 34 years of international experience in the pharmaceutical industry across the United States and Europe. Before co-founding the organization, Mr. Cherian served as Director and Senior Fellow at a leading global pharmaceutical company. During his tenure, he played a key role in early stage product development and successfully coordinated research efforts across multiple global Pfizer sites. His extensive expertise in complex pharmaceutical products continues to support the development of innovative therapies across several therapeutic areas. Mr. Cherian is a recognized expert in drug device combination products and is a leader in advancing differentiated drug delivery systems, contributing to the development of high-value, advanced pharmaceutical solutions. He holds a Ph.D. in Chemical Engineering from the University of Rhode Island and is an inventor with multiple patents. Widely regarded as a thought leader in the industry, he regularly speaks at global pharmaceutical forums and serves on the Executive Committee of the International Pharmaceutical Society. enhance community well being.

Mohamed AlNadi Vice President, International Expansion and Partnerships (MENA and Africa) Dr. Mohamed Alnadi serves as the Vice President of International Expansion and Partnerships for the MENA and Africa regions. With over 25 years of experience in international trade, export operations, and strategic market growth, he has successfully expanded business footprints across more than 60 countries. Since 2002, Dr. Alnadi has led Alnadi Pharmacy Company, establishing it as a trusted name in the pharmaceutical and healthcare sectors. He previously held the position of Managing Director at EgyBelg for Industrial Investment, where he specialized in biotechnology and enzyme production. He also managed a leading food manufacturing company, driving its expansion across regional and global markets. Dr. Alnadi holds a Bachelor’s degree in Pharmacy from Cairo University and a Business Administration Diploma from the American University in Cairo.